| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
a Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; b Pre-clinical Research and Development, F. Hoffmann-La Roche Ltd., Basel, Switzerland; c Roche Diagnostics GmbH, Pharma Research Penzberg, Penzberg, Germany
Key Words. Bone metastases • Bisphosphonates • Ibandronate • Renal safety • Preclinical
Correspondence: Jean-Jacques Body, M.D., Ph.D., Institut Jules Bordet, Université Libre de Bruxelles, 1 Rue Héger-Bordet, 1000 Brussels, Belgium. Telephone: 32-2-541-3303; Fax: 32-2-541-3311; e-mail: jj.body{at}bordet.be
Renal insufficiency is not rare in cancer patients who may receive nephrotoxic medications as antineo-plastic agents or for comorbid conditions. Thus, the choice of a particular bisphosphonate for patients with metastatic bone disease should be based not only on efficacy but also on the risk for renal deterioration. Some i.v. bisphosphonates have been associated with occasional renal toxicity in the clinical setting. Preclinical studies have also shown that there may be considerable differences among bisphosphonate renal safety profiles. Comparative studies show variations in the risk for histopathologic damage and the ability to cause cumulative toxicity during intermittent dosing. Reasons for the differences among bisphosphonates are not fully understood; however, research shows that they may be influenced by pharmacokinetic properties such as renal tissue half-life or protein binding and intracellular potency. Further preclinical analyses are needed to confirm and evaluate differences among bisphosphonates.
This article has been cited by other articles:
![]() |
H. M. Weiss, U. Pfaar, A. Schweitzer, H. Wiegand, A. Skerjanec, and H. Schran Biodistribution and Plasma Protein Binding of Zoledronic Acid Drug Metab. Dispos., October 1, 2008; 36(10): 2043 - 2049. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. D. Ottewell, H. Monkkonen, M. Jones, D. V. Lefley, R. E. Coleman, and I. Holen Antitumor Effects of Doxorubicin Followed by Zoledronic Acid in a Mouse Model of Breast Cancer J Natl Cancer Inst, August 20, 2008; 100(16): 1167 - 1178. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. von Moos, C. B. Caspar, B. Thurlimann, R. Angst, R. Inauen, R. Greil, B. Bergstrom, K. Schmieding, and M. Pecherstorfer Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study Ann. Onc., July 1, 2008; 19(7): 1266 - 1270. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. A. Guise Bone Loss and Fracture Risk Associated with Cancer Therapy Oncologist, November 1, 2006; 11(10): 1121 - 1131. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Q. Lacy, A. Dispenzieri, M. A. Gertz, P. R. Greipp, K. L. Gollbach, S. R. Hayman, S. Kumar, J. A. Lust, S. V. Rajkumar, S. J. Russell, et al. Mayo Clinic Consensus Statement for the Use of Bisphosphonates in Multiple Myeloma Mayo Clin. Proc., August 1, 2006; 81(8): 1047 - 1053. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-J. Body Bisphosphonates in Metastatic Bone Disease: Renal Safety Matters Oncologist, October 1, 2005; 10(suppl_1): 1 - 2. [Full Text] [PDF] |
||||
![]() |
G. H. Jackson Renal Safety of Ibandronate Oncologist, October 1, 2005; 10(suppl_1): 14 - 18. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| THE ONCOLOGIST | STEM CELLS | CME | ALPHAMED PRESS JOURNALS |